Maximal Rate of Force Development of Ankle Muscles and Functional Ability in Patients With Knee Osteoarthritis

Sponsor
Ahram Canadian University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06063889
Collaborator
(none)
126
1
2.4
51.8

Study Details

Study Description

Brief Summary

This study is a detailed assessment of the maximal rate of force development of ankle muscles and its association with functional ability in patients with knee osteoarthritis (OA).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Maximal Rate of Force Development Test for Ankle Muscles

Detailed Description

This research is designed to study the link between force development in ankle muscles and functional abilities in knee OA patients. It aims to understand the influence of ankle muscle strength, specifically plantar flexors, on the stability, pain, and functionality of patients with knee OA. The study will analyze the rate of force development, its importance in explosive strength improvement, and impact on preventing knee injuries. Furthermore, it will investigate the compensatory mechanism of the plantar flexors developed by patients in advanced stages to balance other muscle failures.

Study Design

Study Type:
Observational
Anticipated Enrollment :
126 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Assessment of Maximal Rate of Force Development of Ankle Muscles and Its Association Functional Ability in Patients With Knee Osteoarthritis
Actual Study Start Date :
Jul 20, 2023
Anticipated Primary Completion Date :
Oct 2, 2023
Anticipated Study Completion Date :
Oct 2, 2023

Arms and Interventions

Arm Intervention/Treatment
Knee OA Patients

This group consists of patients who have been diagnosed with knee osteoarthritis. They will be subjected to a series of tests to assess the maximal rate of force development of ankle muscles and their functional abilities.

Diagnostic Test: Maximal Rate of Force Development Test for Ankle Muscles
This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.

Healthy Control

This group will include healthy individuals without knee osteoarthritis. They will undergo the same series of tests to serve as a control group, enabling the comparison of results with the Knee OA Patients group.

Diagnostic Test: Maximal Rate of Force Development Test for Ankle Muscles
This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.

Outcome Measures

Primary Outcome Measures

  1. Knee Osteoarthritis Outcome Score (KOOS) [Baseline]

    The KOOS is a questionnaire that assesses five aspects of knee injury and osteoarthritis: pain, symptoms, ADL function, sport and recreation function, and quality of life. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems. Higher scores indicate better function and less pain.

  2. Forward Step Down Test (FSDT) [Baseline]

    This functional ability test requires participants to perform as many repetitions as possible in 30 seconds of a specific movement. The number of valid repetitions performed in this duration is recorded.

  3. Single Leg Hop Test (SLHT) [Baseline]

    n this test, participants hop forward as far as possible on one leg, and the distance hopped is recorded.

  4. Isokinetic Testing Procedures [Baseline]

    This procedure involves conducting tests of three (60°/s) or five (120°/s) maximal nonconsecutive efforts with specific rest intervals. Each subject is instructed to exert maximal effort throughout the whole range of motion.

  5. Rate of Force Development (RFD) [Baseline]

    The RFD is a measure of the speed at which the force of a muscle contraction develops. It is typically measured during isometric contractions and provides information about the muscle's explosive strength capacity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Group 1 (Knee OA group)
  1. Patients diagnosed with knee osteoarthritis according to Performance of the 2018 classification criteria for early stage knee OA was tested using data from the Osteoarthritis Initiative (OAI (Leung et al.,2020).

  2. Grade 2-3 KOA cases according to Kelgren-Lawrance classification

  3. Having knee pain for at least 6 months.

  4. The visual analog scale (VAS) score being at least 3 or more.

  • Group 2 (Healthy control group) 1. Individuals with no signs or symptoms of Knee OA or other neurological or musculoskeletal conditions.
Exclusion Criteria:
  1. Patellar subluxation

  2. Surgery in any joint of the lower limb

  3. Meniscal injury

  4. Ligament instability

  5. Patients who received intra-articular injection in the knee in the last 6 months

  6. Patients with problems in the hip and ankle

  7. Patients who participated in in another physical therapy program in the last 3 months were not included in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Outpatient clinic of faculty of physical therapy, Ahram Canadian University Al Ḩayy Ath Thāmin Giza Egypt 3221405

Sponsors and Collaborators

  • Ahram Canadian University

Investigators

  • Study Chair: Abeer Abdelrahman, Ph.D, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mohamed Magdy ElMeligie, Director of Electromyography lab, Ahram Canadian University
ClinicalTrials.gov Identifier:
NCT06063889
Other Study ID Numbers:
  • 012/90002023
First Posted:
Oct 3, 2023
Last Update Posted:
Oct 3, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2023